Foresight Diagnostics

Foresight Diagnostics

  • Founded: 2020
  • Location: Aurora, CO
  • Employee range: 11 - 50
  • Funding: $58.8M B Apr 2023; $12.5M A Jun 2021
  • Investors: Foresite Capital, Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, The University of Colorado Healthcare Innovation Fund

job board

Short description:

Cancer Diagnostics

Drug notes:

Contact us to add description:

Long description:

Foresight Diagnostics is a cancer diagnostics company developing a novel liquid biopsy test to detect relapse sooner. Foresight’s approach is a highly sensitive liquid biopsy minimal residual disease (MRD) test that is optimized to detect even the earliest hints of cancer relapse. The test uses Foresight’s patented PhasED-seq technology that leverages the sequencing of phased variants for ultrasensitive and highly specific detection of circulating tumor DNA (ctDNA). This enables detection of ctDNA at levels below one part-per-million. The MRD technology has been validated in thousands of patient samples with B-cell malignancies, lung cancer and breast cancer


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy